Inicio・Lista de Acciones・Genmab A-S

Genmab A-S

Abierto

2,274 -1.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2255

Máximo

2330

Métricas clave
By Trading Economics
Ingresos	243M 295M
Ventas	259M 1.2B
P/B Media del Sector	27.397 55.725
BPA	34.85
Margen de beneficios	25.541
Empleados	3,119
EBITDA	216M 431M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-1.49% downside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	26B 139B
Apertura anterior	2275.13
Cierre anterior	2274

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 sept 2026, 23:56 UTC

In after-market trading, Interactive Brokers Group Inc is roughly flat, with price fluctuations reflecting minimal movement since Wednesday's close.

23 sept 2026, 23:56 UTC

Correlated Moves

Allegiant Travel Co is trading modestly higher in after-market hours, recovering from earlier losses and currently positioned in the middle of its one-month trading range.

23 sept 2026, 23:56 UTC

Arrowhead Pharmaceuticals Inc saw a modest decline in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

23 sept 2026, 23:56 UTC

Dow Inc saw a slight decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month range.

23 sept 2026, 23:55 UTC

Rush Street Interactive Inc. is trading roughly flat during after-market hours, following eight consecutive sessions with lower closes and remaining below its 20-day moving average.

23 sept 2026, 23:55 UTC

Endava PLC is seeing a slight decline in after-market trading, continuing a trend of lower daily closes and trading below its 20-day moving average.

23 sept 2026, 23:55 UTC

Delek US Holdings Inc is trading modestly higher during after-market hours, recovering from earlier declines while remaining below its 20-day moving average.

23 sept 2026, 23:55 UTC

Macro News

The U.S. Dollar Index is trading roughly flat, with macroeconomic developments highlighting oil supply from the Strait of Hormuz amid rising U.S. crude inventories.

23 sept 2026, 23:55 UTC

Cardinal Health Inc is trading modestly higher in after-market hours following slight fluctuations during the session, remaining below its 20-day moving average.

23 sept 2026, 23:52 UTC

Northrop Grumman Corp is declining in after-market trading, settling lower after briefly turning positive and remaining below its 20-day moving average.

23 sept 2026, 23:52 UTC

South Africa's Balance of Trade Data Release on September 30: Market Eyes Sustained Surplus Amid Mixed Economic Signals.

23 sept 2026, 23:52 UTC

Germany's Inflation Rate Expected to Remain Stable Ahead of September 30 Release Amid Geopolitical Tensions and Strong Manufacturing Activity

23 sept 2026, 23:52 UTC

Germany's Inflation Rate Release on September 30 Expected to Show Stability Amid Strong Manufacturing Growth and Geopolitical Tensions.

23 sept 2026, 23:52 UTC

Mixed Sentiment Ahead of U.S. New Home Sales Data Release Amidst Slowing Activity and Luxury Market Resilience

23 sept 2026, 23:52 UTC

New Home Sales Expected at 0.62 Million Amid Rising Prices and Cautious Market Sentiment

23 sept 2026, 23:52 UTC

Japan's Tankan Large Manufacturers Index set for release on September 30, amid mixed market sentiments influenced by global economic factors and rising interest rate concerns.

23 sept 2026, 23:51 UTC

Cleveland-Cliffs Inc has traded lower in after-market hours, pulling back from earlier highs while remaining above its 20-day moving average.

23 sept 2026, 23:51 UTC

Urban Outfitters Inc. is declining in after-market trading, falling significantly below its 20-day moving average and nearing the lower end of its one-month range.

23 sept 2026, 23:51 UTC

Guidewire Software Inc's shares are trading modestly higher in after-market hours, continuing a trend of gradual increases since Wednesday's close.

23 sept 2026, 23:51 UTC

Conagra Brands Inc is seeing modest declines in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

23 sept 2026, 23:51 UTC

Frontdoor Inc's shares advanced modestly in after-market trading, achieving nearly a 1% cumulative return since Wednesday's close, despite trading near the lower end of its range.

23 sept 2026, 23:51 UTC

Nu Holdings Ltd. saw a modest increase in after-market trading, recovering from a low point and marking a cumulative return of nearly 1%.

23 sept 2026, 23:51 UTC

West Pharmaceutical Services Inc is seeing a modest decline in after-market trading, positioned at the lower end of today's range but above its 20-day moving average.

23 sept 2026, 23:51 UTC

Cable One Inc is trading modestly higher in after-market hours, following a notable peak shortly after the regular session ended.

23 sept 2026, 23:51 UTC

Vertex Pharmaceuticals Inc saw a modest rise in after-market trading, recovering from a low return shortly after the market closed.

23 sept 2026, 23:46 UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

23 sept 2026, 23:46 UTC

Boyd Gaming Corp declined in after-market trading, moving from a slight gain to a loss, and is significantly below its 20-day moving average.

23 sept 2026, 23:46 UTC

Repligen Corp's stock declined in after-market trading, hitting its lowest point of the day after Wednesday's close, despite remaining above its 20-day moving average.

23 sept 2026, 23:46 UTC

CEVA Inc is trading modestly higher in after-market hours, maintaining strength above its 20-day moving average amid positive private sector activity indicators.

23 sept 2026, 23:46 UTC

Sirius XM Holdings Inc is down in after-market trading, marking four consecutive sessions of declines and remaining below its 20-day moving average.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Genmab A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.